Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Eli Lilly CEO: Our pill supply can 'reach the planet'
12:09pm, Wednesday, 01'st Apr 2026
Eli Lilly Chair & CEO Dave Ricks tells CNBC's Angelica Peebles that with the approval of the company's GLP-1 pill, orforglipron, they already have the scale necessary to supply the medicine to the glo
Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial1 Foundayo, Lilly's second FDA-approved obesity medicine, will be available via LillyDirect ® wit
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
11:28am, Wednesday, 01'st Apr 2026
The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for convenienc
Lexaria to Begin New Human Clinical Study in GLP-1
09:20am, Wednesday, 01'st Apr 2026
Contracts signed for Human Pilot Study #7 (GLP-1-H26-7) KELOWNA, BC / ACCESS Newswire / April 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
07:35am, Wednesday, 01'st Apr 2026
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech lands
Down 13% in 4 Weeks, Here's Why Global Partners (GLP) Looks Ripe for a Turnaround
10:36am, Tuesday, 31'st Mar 2026
Global Partners (GLP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
03:05am, Monday, 30'th Mar 2026
VANCOUVER, BC / ACCESS Newswire / March 30, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery sys
Global Partners: Resilient High-Yield Play Trading Below Intrinsic Value
08:11am, Saturday, 28'th Mar 2026
Global Partners LP remains a Strong Buy, offering a resilient business model, robust yield, and trading at a discount to intrinsic value. GLP's distribution yield stands at ~6.76% today, with 17 conse
Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster
08:15am, Friday, 27'th Mar 2026
Structure Therapeutics reported Phase 2 data for Aleniglipron, showing 16% weight loss at 44 weeks with strong tolerability and no safety signals. Aleniglipron's best-in-class oral efficacy, low disco
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
04:05pm, Thursday, 26'th Mar 2026
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapita
Novo Nordisk's FDA-Approved GLP-1s Now Available With Hims & Hers
12:00pm, Thursday, 26'th Mar 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications are available to eligible customers, incl
Should Value Investors Buy Global Partners (GLP) Stock?
10:42am, Thursday, 26'th Mar 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Novo Nordisk GLP-1 pipeline shows promise but oral drug trends give analysts pause
08:36am, Thursday, 26'th Mar 2026
Novo Nordisk (NYSE:NVO) has received a broadly neutral assessment from Deutsche Bank and Citi after a series of clinical and commercial updates, with both brokers flagging encouraging but not transfor
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
04:05pm, Wednesday, 25'th Mar 2026
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Cal
3 Reasons Why Growth Investors Shouldn't Overlook Global Partners (GLP)
01:46pm, Wednesday, 25'th Mar 2026
Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.
